In contrast to the high prevalence of UBE2T, UBE2C, and BIRC5 amplifications in BC patients, only 2/49 cell lines (JIMT-1 and HCC1569) harbored UBE2C amplifications and 3/49 cell lines (HCC1143, OCUB-M, and MDA-MB-361) harbored BIRC5 amplifications (Figure 8a; Table S4). Here, BIRC5 is linked to breast cancer.